drugset / Trial / NCT02324335

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

NCT02324335

Phase 2 Completed 61 enrolled Innovation Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral mucositis in patients undergoing chemoradiation for treatment of head and neck cancer.

Timeline

Start
2014-08-14
Primary completion
2017-10-25
Completion
2017-11-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brilacidin Other / unclassified 3 mg/ml Oral